Alliance A Randomized Phase 2/3 Study of the Bispecific Antibody (BsAb), Glofitamab, plus Chemoimmunotherapy in Newly Diagnosed and Relapsed Burkitt and High-Grade (Double Hit) B-cell Lymphomas with MYC and BCL2 Rearrangements Adult CIRB - Late Phase Emphasis Active Available to Open